MRK US58933Y1055

Report

Delayed Nyse - 06/23 04:10:00 pm
75.58	USD		-0.80%

04:15p

RUBIUS THERAPEUTICS : First Patient Dosed in Rubius Therapeutics' Trial For Advanced Solid Tumors Treatment

10:17a

MERCK : Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival in Patients With Persistent Recurrent or Metastatic Cervical Cancer

04:52a

BAYER : Merck & Co Heart Failure Drug Verquvo Wins Japanese Approval

Summary

Quotes 5-day view Delayed Quote.

Delayed Nyse

06/17/2021	06/18/2021	06/21/2021	06/22/2021	06/23/2021	Date
77.23(c)	76.61(c)	76.75(c)	76.19(c)	75.58(c)	Last
14 233 205	19 351 902	10 880 842	10 957 476	9 516 720	Volume
+0.81%	-0.80%	+0.18%	-0.73%	-0.80%	Change

More quotes

Estimated financial data (e) (USD)

Sales 2021	48 016 M - -
Net income 2021	12 084 M - -
Net Debt 2021	11 622 M - -
P/E ratio 2021	15,6x
Yield 2021	3,44%

Sales 2022	50 139 M - -
Net income 2022	13 724 M - -
Net Debt 2022	5 995 M - -
P/E ratio 2022	13,5x
Yield 2022	3,71%

Capitalization	191 B 191 B -
EV / Sales 2021	4,23x
EV / Sales 2022	3,94x
Nbr of Employees	73 500
Free-Float	70,7%

More Financials

Company

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and...

Sector

Pharmaceuticals

Calendar

06/22 | 09:00am

Investor Meeting

More about the company

Ratings of Merck & Co., Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

B-

More Ratings

All news about MERCK & CO., INC.

04:15p	RUBIUS THERAPEUTICS : First Patient Dosed in Rubius Therapeutics' Trial For Adv..	MT
10:17a	MERCK : Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overa..	AQ
04:52a	BAYER : Merck & Co Heart Failure Drug Verquvo Wins Japanese Approval	MT
06/22	MERCK : Says Phase 3 Trial Met Endpoints of Overall Survival, Progression-Free ..	MT
06/22	MERCK : Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overa..	BU
06/22	Merck's Keytruda Meets Main Endpoints in Cervical-Cancer Study	DJ
06/22	ASTRAZENECA : Gets European Commission's Conditional Approval for Koselugo in P..	MT
06/22	ASTRAZENECA : Merck & Co. Win Conditional EU Nod for Rare Disease Drug in Child..	MT
06/21	MERCK : CONSOLIDATED STATEMENT OF INCOME - GAAP (Form 8-K)	PU
06/21	MERCK & CO., INC. : Regulation FD Disclosure, Financial Statements and Exhibits..	AQ
06/17	MERCK : Unveils Supply Deal With US Government for Investigational Therapy Moln..	MT
06/17	MERCK : to Participate in the Guggenheim Biopharma Strategy Series	BU
06/16	MERCK : Announces the Kenneth C. Frazier Award for Maternal Health Equity to Ac..	BU
06/14	MERCK & CO., INC. : Ex-dividend day for	FA
06/09	MERCK : to Supply COVID-19 Drug Molnupiravir to US for $1.2 Billion	MT

More news

News in other languages on MERCK & CO., INC.

04:06a	Bayer-Herzmedikament Verquvo in Japan zugelassen
06/22	MERCK : nouvel essai prometteur pour Keytruda
06/22	Keytruda von Merck & Co auch gegen Gebärmutterhalskrebs wirksam
06/19	LEVOTHYROX : nouveau sursis pour l'ancienne formule, disponible jusqu'à fin 2022
06/17	USA investieren 3,2 Milliarden Dollar in Entwicklung antiviraler Medikamente

More news

Analyst Recommendations on MERCK & CO., INC.

06/09	MERCK : JPMorgan Adjusts Merck's Price Target to $100 From $105, Maintains Over..	MT
06/08	MERCK : Price Target From RBC Cut to $75 From $77 to Reflect Organon Spinoff, S..	MT
06/07	MERCK : Truist Securities Adjusts Merck's Price Target to $93 From $96, Maintai..	MT

More recommendations

Provided by Scoopnest.com

Analysis

Exclusive-BlackRock backs 3 dissidents to shake up Exxon board -sources